Skip to main content
Tom H. Greene

Tom H. Greene, PhD

Languages spoken: English

Academic Information

Departments Primary - Population Health Sciences , Adjunct - Family & Preventive Medicine , Primary - Internal Medicine

Divisions: Epidemiology , Public Health

Academic Office Information

Dr. Tom Greene is a Professor of the Division of Biostatistics in the Department of Population Health Sciences, and a Professor in the Division of Epidemiology of the Department of Internal Medicine. He is also Director of the Population Health Research Foundation in the Utah Center for Clinical and Translational Science, and currently holds an H.A. and Edna Benning Endowed Chair. Dr. Greene received his PhD in Statistics from Cornell University in 1985, and worked as an Assistant Professor in the Department of Statistics at the University of Kentucky from 1985 to 1989. He then served as a statistician at Case Western University and the Cleveland Clinic Foundation from 1989 through 2006, where he was the lead statistician on a substantial number of multi-center clinical trials, primarily in the field of Nephrology. Dr. Greene was the acting head of the Cleveland Clinic’s Cancer Biostatistics Core for 2 years from 1991-1993. Dr. Greene moved to the University of Utah in 2006, where he founded the Study Design and Biostatistics Center and subsequently the Population Health Research Foundation.

Dr. Greene serves as the lead statistician on many research projects in collaboration with clinical and translational investigators across the University of Utah and elsewhere, and carries out methodological research in the areas of clinical trial design, causal inference, and validation of surrogate endpoints. Dr. Greene is also a member of the Cancer Biostatistics Resource, and is involved in the design and analysis of a sequential, multiple assignment, randomized trial to promote smoking cessation. He is particularly interested in the problem of integrating information from multiple surrogate and clinical endpoints to evaluate treatment efficacy in randomized clinical trials.

Education History

Doctoral Training Cornell University
Cornell University
Undergraduate University of Kentucky

Selected Publications

Journal Article

  1. Heerspink HJL, Jongs N, Neuen BL, Schloemer P, Vaduganathan M, Inker LA, Fletcher RA, Wheeler DC, Bakris G, Greene T, Chertow GM, Perkovic V (2023). Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials. Kidney Int, 104(1), 181-188.
  2. Zheutlin AR, Addo DK, Jacobs JA, Derington CG, Herrick JS, Greene T, Stulberg EL, Berlowitz DR, Williamson JD, Pajewski NM, Supiano MA, Bress AP (2023). Evidence for Age Bias Contributing to Therapeutic Inertia in Blood Pressure Management: A Secondary Analysis of SPRINT. Hypertension, 80(7), 1484-1493.
  3. Derington CG, Bress AP, Berchie RO, Herrick JS, Shen J, Ying J, Greene T, Tajeu GS, Sakhuja S, Ruiz-Negrn N, Zhang Y, Howard G, Levitan EB, Muntner P, Safford MM, Whelton PK, Weintraub WS, Moran AE, Bellows BK, SPRINT Research Group (2023). Estimated population health benefits of intensive systolic blood pressure treatment among SPRINT-eligible US adults. Am J Hypertens.
  4. Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, Badve SV, Caravaca-Fontn F, Del Vecchio L, Floege J, Goicoechea M, Haaland B, Herrington WG, Imai E, Jafar TH, Lewis JB, Li PKT, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Wetzels JFM, Woodward M, Heerspink HJL, CKD-EPI Clinical Trials Consortium (2023). A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med.
  5. Heerspink HJL, Inker LA, Tighiouart H, Collier WH, Haaland B, Luo J, Appel GB, Chan TM, Estacio RO, Fervenza F, Floege J, Imai E, Jafar TH, Lewis JB, Kam-Tao Li P, Locatelli F, Maes BD, Perna A, Perrone RD, Praga M, Schena FP, Wanner C, Xie D, Greene T, CKD-EPI CT (2023). Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD. J Am Soc Nephrol, 34(6), 955-968.
  6. van der Hoek S, Jongs N, Oshima M, Neuen BL, Stevens J, Perkovic V, Levin A, Mahaffey KW, Pollock C, Greene T, Wheeler DC, Jardine MJ, Heerspink HJL (2023). Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial. Clin J Am Soc Nephrol, 18(6), 748-758.
  7. Kang A, Smyth B, Neuen BL, Heerspink HJL, Di Tanna GL, Zhang H, Arnott C, Hockham C, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Mahaffey KW, Perkovic V, Jardine MJ (2023). The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials. Diabetes Obes Metab.
  8. Ghazi L, Shen J, Ying J, Derington CG, Cohen JB, Marcum ZA, Herrick JS, King JB, Cheung AK, Williamson JD, Pajewski NM, Bryan N, Supiano M, Sonnen J, Weintraub WS, Greene TH, Bress AP (2023). Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit: A Secondary Analysis of the SPRINT Randomized Clinical Trial. JAMA Netw Open, 6(5), e2314443.
  9. Jones BE, Ying J, Nevers M, Rutter ED, Chapman AB, Brenner R, Samore MH, Greene T (2022). Hospital admission decisions for older Veterans with community-onset pneumonia: An analysis of 118 U.S. Veterans Affairs Medical Centers. Acad Emerg Med, 30(4), 398-409.
  10. Eneanya ND, Adingwupu OM, Kostelanetz S, Norris KC, Greene T, Lewis JB, Beddhu S, Boucher R, Miao S, Chaudhari J, Levey AS, Inker LA (2023). Social Determinants of Health and Their Impact on the Black Race Coefficient in Serum Creatinine-Based Estimation of GFR: Secondary Analysis of MDRD and CRIC Studies. Clin J Am Soc Nephrol, 18(4), 446-454.
  11. Spivak AM, Barney BJ, Greene T, Holubkov R, Olsen CS, Bridges J, Srivastava R, Webb B, Sebahar F, Huffman A, Pacchia CF, Dean JM, Hess R (2023). A Randomized Clinical Trial Testing Hydroxychloroquine for Reduction of SARS-CoV-2 Viral Shedding and Hospitalization in Early Outpatient COVID-19 Infection. Microbiol Spectr, 11(2), e0467422.
  12. Derington CG, Bress AP, Moran AE, Weintraub WS, Herrick JS, Cushman WC, Kronish IM, Stults B, Shimbo D, Muntner P, Greene T, Bates JT, Chang TI, Katz LA, Rehman SU, Roumie CL, Tamariz L, King JB (2022). Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial. Hypertension, 80(3), 590-597.
  13. Fritz JM, Greene T, Brennan GP, Minick K, Lane E, Wegener ST, Skolasky RL (2023). Characterizing modifications to a comparative effectiveness research study: the OPTIMIZE trial-using the Framework for Reporting Adaptations and Modifications to Evidence-based Interventions (FRAME). Trials, 24(1), 137.
  14. Vanneman ME, Rosen AK, Wagner TH, Shwartz M, Gordon SH, Greenberg G, Zheng T, Cook J, Beilstein-Wedel E, Greene T, Kelley AT (2022). Differences Between VHA-Delivered and VHA-Purchased Behavioral Health Care in Service and Patient Characteristics. Psychiatr Serv, 74(2), 148-157.
  15. Bose S, Groat D, Dinglas VD, Akhlaghi N, Banner-Goodspeed V, Beesley SJ, Greene T, Hopkins RO, Mir-Kasimov M, Sevin CM, Turnbull AE, Jackson JC, Needham DM, Brown SM, Addressing Post-Intensive Care Syndrome APICS-01 Study Team (2023). Association Between Unmet Nonmedication Needs After Hospital Discharge and Readmission or Death Among Acute Respiratory Failure Survivors: A Multicenter Prospective Cohort Study. Crit Care Med, 51(2), 212-221.
  16. Collier W, Inker LA, Haaland B, Appel GB, Badve SV, Caravaca-Fontn F, Chalmers J, Floege J, Goicoechea M, Imai E, Jafar TH, Lewis JB, Li PKT, Locatelli F, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Heerspink HJL, Greene T, Chronic Kidney Disease Epidemiology Collaboration CKD-EPI (2023). Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD. Clin J Am Soc Nephrol, 18(2), 183-192.
  17. Baron KG, Appelhans BM, Burgess HJ, Quinn L, Greene T, Allen CM (2023). Circadian Timing, Information processing and Metabolism (TIME) study: protocol of a longitudinal study of sleep duration, circadian alignment and cardiometabolic health among overweight adults. BMC Endocr Disord, 23(1), 26.
  18. Yao Y, Li L, Astor B, Yang W, Greene T (2023). Predicting the risk of a clinical event using longitudinal data: the generalized landmark analysis. BMC Med Res Methodol, 23(1), 5.
  19. Brown SM, Dinglas VD, Akhlaghi N, Bose S, Banner-Goodspeed V, Beesley S, Groat D, Greene T, Hopkins RO, Mir-Kasimov M, Sevin CM, Turnbull AE, Jackson JC, Needham DM, Caraker E, Cherukuri SPS, Kadiri NP, Kalva T, Koneru M, Kota P, Lee EM, Mahmoud MA, Malik A, Nikooie R, Roberts D, Singu S, Vaziri P, Brown K, Daw A, Merrill M, Smith R, Hirshberg E, Butler J, Hoenig B, Karamourtopoulos M, Hays M, Abel R, High C, Beck E, Armbruster B, Applegate D, Fergus M, Kumar N, Roth M, Mogan S, Abel R, De Souza Licht A, Londono I, Larson J, Capers K, Karamourtopoulos M, Hoenig B, Toksoz-Exley A, Crane J (2022). Association between unmet medication needs after hospital discharge and readmission or death among acute respiratory failure survivors: the addressing post-intensive care syndrome (APICS-01) multicenter prospective cohort study. Crit Care, 26(1).
  20. Fritz JM, Del Fiol G, Gibson B, Wetter DW, Solis V, Bennett E, Thackeray A, Goode A, Lundberg K, Romero A, Ford I, Stevens L, Siaperas T, Morales J, Yack M, Greene T (2022). BeatPain Utah: study protocol for a pragmatic randomised trial examining telehealth strategies to provide non-pharmacologic pain care for persons with chronic low back pain receiving care in federally qualified health centers. BMJ Open, 12(11).
  21. Jongs N, Chertow GM, Greene T, McMurray JJV, Langkilde AM, Correa-Rotter R, Kashihara N, Rossing P, Sjstrm CD, Stefnsson BV, Toto RD, Wheeler DC, Heerspink HJL, Hou FF (2022). Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD. J Am Soc Nephrol, 33(11), 2094-2107.
  22. Jones BE, Ying J, Nevers MR, Alba PR, Patterson OV, Peterson KS, Rutter E, Christensen MA, Stern S, Jones MM, Gundlapalli A, Dean NC, Samore MC, Greene T (2022). Trends in Illness Severity, Hospitalization, and Mortality for Community-Onset Pneumonia at 118 US Veterans Affairs Medical Centers. J Gen Intern Med, 37(15), 3839-3847.
  23. Fritz JM, Rhon DI, Garland EL, Hanley AW, Greenlee T, Fino N, Martin B, Highland KB, Greene T (2022). The Effectiveness of a Mindfulness-Based Intervention Integrated with Physical Therapy (MIND-PT) for Post-Surgical Rehabilitation after Lumbar Surgery: A Protocol for a Randomized Controlled Trial as Part of the Back Pain Consortium (BACPAC) Research Program. Pain Med.
  24. Wheeler DC, Jongs N, Stefansson BV, Chertow GM, Greene T, Hou FF, Langkilde AM, McMurray JJV, Rossing P, Nowicki M, Wittmann I, Correa-Rotter R, Sjstrm CD, Toto RD, Heerspink HJL (2022). Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Am J Kidney Dis, 37(9), 1647-1656.
  25. Li JW, Arnott C, Heerspink HJL, Mbiostat QL, Cannon CP, Wheeler DC, Charytan DM, Barraclough J, Figtree GA, Agarwal R, Bakris G, de Zeeuw D, Greene T, Levin A, Pollock C, Zhang H, Zinman B, Mahaffey KW, Perkovic V, Neal B, Jardine MJ (2022). Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial. Am J Kidney Dis, 11(16).
  26. Li Y, He Y, Falzon I, Fairbourn B, Tingey S, Imrey PB, Radeva MK, Beck GJ, Gassman JJ, Roy-Chaudhury P, Berceli SA, Cheung AK, Shiu YT, Feldman H, Dember L, Farber A, Kaufman J, Stern L, LeSage P, Kivork C, Soares D, Malikova M, Allon M, Young C, Taylor M, Woodard L, Mangadi K, Munda R, Lee T, Alloway R, El-Khatib M, Canaan T, Pflum A, Thieken L, Campos-Naciff B, Huber T, Berceli S, Jansen M, McCaslin G, Trahan Y, Vazquez M, Vongpatanasin W, Davidson I, Hwang C, Lightfoot T, Livingston C, Valencia A, Dolmatch B, Fenves A, Hawkins N, Cheung A, Kraiss L, Kinikini D, Treiman G, Ihnat D, Sarfati M, Lavasani I, Maloney M, Schlotfeldt L, Himmelfarb J, Buchanan C, Clark C, Crawford C, Hamlett J, Kundzins J, Manahan L, Wise J, Beck G, Gassman J, Greene T, Imrey P, Li L, Alster J, Li M, MacKrell J, Radeva M, Weiss B, Wiggins K, Alpers C, Hudkins K, Wietecha T, Robbin M, Umphrey H, Alexander L, Abts C, Belt L, Vita J, Hamburg N, Duess M, Levit A, Higgins H, Ke S, Mandaci O, Snell C, Gravley J, Behnken S, Mortensen R, Chertow G, Besarab A, Brayman K (2022). Dynamic Remodeling of Human Arteriovenous Fistula Wall Obtained From Magnetic Resonance Imaging During the First 6 Months After Creation. Am J Kidney Dis, 7(8), 1905-1909.
  27. Cohen JB, Marcum ZA, Zhang C, Derington CG, Greene TH, Ghazi L, Herrick JS, King JB, Cheung AK, Bryan N, Supiano MA, Sonnen JA, Weintraub WS, Scharfstein D, Williamson J, Pajewski NM, Bress AP (2022). Risk of Mild Cognitive Impairment or Probable Dementia in New Users of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: A Secondary Analysis of Data from the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis, 5(7), E2220680.
  28. Marrouche NF, Wazni O, McGann C, Greene T, Dean JM, Dagher L, Kholmovski E, Mansour M, Marchlinski F, Wilber D, Hindricks G, Mahnkopf C, Wells D, Jais P, Sanders P, Brachmann J, Bax JJ, Morrison-De Boer L, Deneke T, Calkins H, Sohns C, Akoum N (2022). Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial. Am J Kidney Dis, 327(23), 2296-2305.
  29. Sisco-Taylor BL, Magel JS, McFadden M, Greene T, Shen J, Fritz JM (2022). Changes in Pain Catastrophizing and Fear-Avoidance Beliefs as Mediators of Early Physical Therapy on Disability and Pain in Acute Low-Back Pain: A Secondary Analysis of a Clinical Trial. Am J Kidney Dis, 23(6), 1127-1137.
  30. Vonesh EF, Greene T (2022). Biased estimation with shared parameter models in the presence of competing dropout mechanisms. Am J Kidney Dis, 78(1), 399-406.
  31. Neuen BL, Tighiouart H, Heerspink HJL, Vonesh EF, Chaudhari J, Miao S, Chan TM, Fervenza FC, Floege J, Goicoechea M, Herrington WG, Imai E, Jafar TH, Lewis JB, Li PKT, Locatelli F, Maes BD, Perrone RD, Praga M, Perna A, Schena FP, Wanner C, Wetzels JFM, Woodward M, Xie D, Greene T, Inker LA (2022). Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. Am J Kidney Dis, 33(2), 291-303.
  32. Marcum ZA, Cohen JB, Zhang C, Derington CG, Greene TH, Ghazi L, Herrick JS, King JB, Cheung AK, Bryan N, Supiano MA, Sonnen JA, Weintraub WS, Williamson J, Pajewski NM, Bress AP (2022). Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors with Cognitive Impairment. Am J Kidney Dis, 5(1), E2145319.
  33. Zheutlin AR, Mondesir FL, Derington CG, King JB, Zhang C, Cohen JB, Berlowitz DR, Anstey DE, Cushman WC, Greene TH, Ogedegbe O, Bress AP (2022). Analysis of Therapeutic Inertia and Race and Ethnicity in the Systolic Blood Pressure Intervention Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open, 5(1), e2143001.
  34. Raimann JG, Chan CT, Daugirdas JT, Depner T, Greene T, Kaysen GA, Kliger AS, Kotanko P, Larive B, Beck G, Lindsay RMG, Rocco MV, Chertow GM, Levin NW (2021). The Predialysis Serum Sodium Level Modifies the Effect of Hemodialysis Frequency on Left-Ventricular Mass: The Frequent Hemodialysis Network Trials. Am J Kidney Dis, 46(6), 768-776.
  35. Delaney RK, Pinto NM, Ozanne EM, Stark LA, Pershing ML, Thorpe A, Witteman HO, Thokala P, Lambert LM, Hansen LM, Greene TH, Fagerlin A (2021). Study protocol for a randomised clinical trial of a decision aid and values clarification method for parents of a fetus or neonate diagnosed with a life-threatening congenital heart defect. BMJ Open, 11(12), e055455.
  36. Beddhu S, Boucher RE, Sun J, Balu N, Chonchol M, Navaneethan S, Chertow GM, Townsend R, Haley W, Cheung AK, Conroy MB, Raj DS, Xu D, George T, Yunis R, Wei G, Canton G, Bates J, Chen J, Papademetriou V, Punzi H, Wiggers A, Wright JT, Greene T, Yuan C (2021). Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes. Am J Kidney Dis, 22(1).
  37. Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjstrm CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL (2021). Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Am J Kidney Dis, 9(11), 755-766.
  38. Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjstrm CD, Stefansson BV, Toto RD, Wheeler DC, Greene T (2021). Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Am J Kidney Dis, 9(11), 743-754.
  39. Samore MH, Looney A, Orleans B, Greene T, Seegert N, Delgado JC, Presson A, Zhang C, Ying J, Zhang Y, Shen J, Slev P, Gaulin M, Yang MJ, Pavia AT, Alder SC (2021). Probability-based estimates of severe acute respiratory syndrome coronavirus 2 seroprevalence and detection fraction, utah, usa. Am J Kidney Dis, 27(11), 2786-2794.
  40. Toth DJA, Beams AB, Keegan LT, Zhang Y, Greene T, Orleans B, Seegert N, Looney A, Alder SC, Samore MH (2021). High variability in transmission of SARS-CoV-2 within households and implications for control. Am J Kidney Dis, 16(11 November).
  41. Schlechter CR, Del Fiol G, Lam CY, Fernandez ME, Greene T, Yack M, Schulthies S, Nelson M, Bohner C, Pruhs A, Siaperas T, Kawamoto K, Gibson B, Nahum-Shani I, Walker TJ, Wetter DW (2021). Application of community - engaged dissemination and implementation science to improve health equity. Prev Med Rep, 24, 101620.
  42. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutirrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS, Chronic Kidney Disease Epidemiology Collaboration (2021). New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med.
  43. Heerspink HJ, Cherney D, Postmus D, Stefnsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJ, Correa-Rotter R, Rossing P, Sjstrm CD, Toto RD, Wheeler DC, DAPA-CKD trial committees and investigators (2021). A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int.
  44. Heerspink HJL, Stack AG, Terkeltaub R, Greene TA, Inker LA, Bjursell M, Perl S, Rikte T, Erlandsson F, Perkovic V, SAPPHIRE investigators (2021). Rationale, design, demographics, and baseline characteristics of the randomised, controlled, phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia. Nephrol Dial Transplant.
  45. Lane E, Magel JS, Thackeray A, Greene T, Fino NF, Puentedura EJ, Louw A, Maddox D, Fritz JM (2021). Effectiveness of training physical therapists in pain neuroscience education for patients with chronic spine pain: cluster-randomized trial. Pain.
  46. Wohlfahrt P, Nativi-Nicolau J, Zhang M, Selzman CH, Greene T, Conte J, Biber JE, Hess R, Mondesir FL, Wever-Pinzon O, Drakos SG, Gilbert EM, Kemeyou L, LaSalle B, Steinberg BA, Shah RU, Fang JC, Spertus JA, Stehlik J (2022). Quality of Life in Patients With Heart Failure With Recovered Ejection Fraction. JAMA Cardiol, 6(8), 957-962.
  47. Steinberg BA, Zhang M, Bensch J, Lyons A, Bunch TJ, Piccini JP, Siu A, Spertus JA, Stehlik J, Wohlfahrt P, Greene T, Hess R, Fang JC (2021). Quantifying the Impact of Atrial Fibrillation on Heart Failure-Related Patient-Reported Outcomes in the Utah mEVAL Program. J Card Fail, 28, 13-20.
  48. Wheeler DC, Toto RD, Stefnsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Pecoits-Filho R, Correa-Rotter R, Rossing P, Sjstrm CD, Umanath K, Langkilde AM, Heerspink HJL (2021). A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Am J Kidney Dis, 100(1), 215-224.
  49. Jones BE, Ying J, Nevers M, Alba PR, He T, Patterson OV, Jones MM, Stevens V, Shen J, Humpherys J, Peterson KS, Rutter ED, Gundlapalli AV, Weir CR, Dean NC, Fine MJ, Samore MC, Greene TH (2021). Computerized Mortality Prediction for Community-acquired Pneumonia at 117 Veterans Affairs Medical Centers. Ann Am Thorac Soc, 18(7), 1175-1184.
  50. Vonesh EF, Greene T (2021). Correction: Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease (Statistics in Medicine, (2019), 38, 22, (4218-4239), 10.1002/sim.8282). Am J Kidney Dis, 40(14), 3400-3401.
  51. Inker LA, Couture SJ, Tighiouart H, Abraham AG, Beck GJ, Feldman HI, Greene T, Gudnason V, Karger AB, Eckfeldt JH, Kasiske BL, Mauer M, Navis G, Poggio ED, Rossing P, Shlipak MG, Levey AS, Andresdottir MB, Gudmundsdottir H, Indridason OS, Palsson R, Kimmel P, Weir M, Kalil R, Pesavento T, Porter A, Taliercio J, Hsu Cy, Chen J, Sinkeler S, Wyatt C, Krishnasami Z, Hellinger J, Margolick J, Kingsley L, Witt M, Wolinsky S, Shafi T, Post W, Doria A, Parving HH (2021). A New Panel-Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population. Am J Kidney Dis, 77(5), 673-683.e1.
  52. Nelson RE, Montgomery AE, Suo Y, Cook J, Pettey W, Gundlapalli A, Greene T, Evans W, Gelberg L, Kertesz SG, Tsai J, Byrne TH (2021). Temporary financial assistance decreased health care costs for veterans experiencing housing instability. Am J Kidney Dis, 40(5), 820-828.
  53. Bress AP, Greene T, Derington CG, Shen J, Xu Y, Zhang Y, Ying J, Bellows BK, Cushman WC, Whelton PK, Pajewski NM, Reboussin D, Beddu S, Hess R, Herrick JS, Zhang Z, Kolm P, Yeh RW, Basu S, Weintraub WS, Moran AE (2021). Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events. Am J Kidney Dis, 77(16), 1977-1990.
  54. Oshima M, Jardine MJ, Agarwal R, Bakris G, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Lim SK, Mahaffey KW, Neal B, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Perkovic V, Heerspink HJL (2021). Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Am J Kidney Dis, 99(4), 999-1009.
  55. Marrouche NF, Greene T, Dean JM, Kholmovski EG, Boer LMd, Mansour M, Calkins H, Marchlinski F, Wilber D, Hindricks G, Mahnkopf C, Jais P, Sanders P, Brachmann J, Bax J, Dagher L, Wazni O, Akoum N (2021). Efficacy of LGE-MRI-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: The DECAAF II trial: Study design. Am J Kidney Dis, 32(4), 916-924.
  56. Cho ME, Sweeney C, Fino N, Greene T, Ramkumar N, Huang Y, Ricardo AC, Shafi T, Deo R, Anderson A, Mills KT, Cheung AK (2021). Longitudinal changes in prorenin and renin in the chronic renal insufficiency cohort. Am J Kidney Dis, 52(2), 141-151.
  57. Heerspink HJL, Sjstrm CD, Jongs N, Chertow GM, Kosiborod M, Hou FF, McMurray JJV, Rossing P, Correa-Rotter R, Kurlyandskaya R, Stefansson BV, Toto RD, Langkilde AM, Wheeler DC, Heerspink HJL, Wheeler DC, Chertow GM, Correa-Rotter R, Greene T, McMurray J, Rossing P, Toto R, Stefansson BV, Maria Langkilde A, Maffei LE, Raffaele P, Solis SE, Arias CA, Aizenberg D, Luquez C, Zaidman C, Cluigt N, Mayer M, Alvarisqueta A, Wassermann A, Maldonado R, Bittar J, Maurich M, Gaite LE, Garcia N, Sivak L, Ramallo PO, Santos JC, Garcia Duran R, Oddino JA, Maranon A, Maia LN, D Avila D, Barros EJG, Vidotti MH, Panarotto D, Noronha IDL, Turatti LAA, Deboni L, Canziani ME, Riella MC, Bacci MR, Paschoalin RP, Franco RJ, Goldani JC, St-Amour E, Steele AW, Goldenberg R, Pandeya S, Bajaj H, Cherney D, Kaiser SM, Conway JR, Chow SS, Bailey G, Lafrance J, Winterstein J, Cournoyer S, Gaudet D, Madore F, Houlden RL, Dowell A, Langlois M, Muirhead N, Khandwala H, Levin A, Xue Y, Zuo L, Hao C, Ni Z, Xing C, Chen N, Dong Y, Zhou R, Xiao X, Zou Y, Wang C, Liu B, Chen Q, Lin M, Luo Q, Zhang D, Wang J, Chen M, Wang X (2021). Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial. Am J Kidney Dis, 42(13), 1216-1227.
  58. McMurray JJVWheeler DCStefnsson BVJongs NPostmus DCorrea-Rotter RChertow GMGreene THeld CHou FFMann JFERossing PSjstrm CDToto RDLangkilde AMHeerspink HJL (2021). Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation, 143(5), 438-448.
  59. Brintz BJHaaland BHoward JChao DLProctor JLKhan AIAhmed SMKeegan LTGreene TKeita AMKotloff KLPlatts-Mills JANelson EJLevine ACPavia ATLeung DT (2021). A modular approach to integrating multiple data sources into real-time clinical prediction for pediatric diarrhea. Elife, 10, 1-18.
  60. Jardine MZhou ZLambers Heerspink HJHockham CLi QAgarwal RBakris GLCannon CPCharytan DMGreene TLevin ALi JWNeuen BLNeal BOh ROshima MPollock CWheeler DCde Zeeuw DZhang HZinman BMahaffey KWPerkovic V (2021). Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis. Clin J Am Soc Nephrol, 16(3), 384-395.
  61. Cho MEHansen JLSauer BCCheung AKAgarwal AGreene T (2021). Heart failure hospitalization risk associated with iron status in veterans with ckd. Clin J Am Soc Nephrol, 16(4), 522-531.
  62. Lyden KBoucher RWei GZhou NChristensen JChertow GMBeddhu SGreene T (2021). Targeting sedentary behavior in ckd a pilot and feasibility randomized controlled trial. Clin J Am Soc Nephrol, 16(5), 717-726.
  63. Fritz JM, Lane E, McFadden M, Brennan G, Magel JS, Thackeray A, Minick K, Meier W, Greene T (2020). Physical Therapy Referral From Primary Care for Acute Back Pain With Sciatica : A Randomized Controlled Trial. Ann Intern Med, 174(1), 8-17.
  64. Fritz JM, Rhon DI, Teyhen DS, Kean J, Vanneman ME, Garland EL, Lee IE, Thorp RE, Greene TH (2020). A Sequential Multiple-Assignment Randomized Trial (SMART) for Stepped Care Management of Low Back Pain in the Military Health System: A Trial Protocol. Pain Med, 21(Suppl 2), S73-S82.
  65. Bakris GOshima MMahaffey KWAgarwal RCannon CPCapuano GCharytan DMde Zeeuw DEdwards RGreene THeerspink HJLLevin ANeal BOh RPollock CRosenthal NWheeler DCZhang HZinman BJardine MJPerkovic V (2020). Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial. Clin J Am Soc Nephrol, 15(12), 1705-1714.
  66. Edmonston DL, Roe MT, Block G, Conway PT, Dember LM, DiBattiste PM, Greene T, Hariri A, Inker LA, Isakova T, Montez-Rath ME, Nkulikiyinka R, Polidori D, Roessig L, Tangri N, Wyatt C, Chertow GM, Wolf M (2020). Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. Am J Kidney Dis, 76(6), 842-850.
  67. Oshima M, Neuen BL, Li J, Perkovic V, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Mahaffey KW, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Jardine MJ, Heerspink HJL (2020). Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. J Am Soc Nephrol, 31(12), 2925-2936.
  68. Zenger B, Zhang M, Lyons A, Bunch TJ, Fang JC, Freedman RA, Navaravong L, Piccini JP, Ranjan R, Spertus JA, Stehlik J, Turner JL, Greene T, Hess R, Steinberg BA (2020). Patient-reported outcomes and subsequent management in atrial fibrillation clinical practice: Results from the Utah mEVAL AF program. J Cardiovasc Electrophysiol, 31(12), 3187-3195.
  69. Xu Y, Greene TH, Bress AP, Sauer BC, Bellows BK, Zhang Y, Weintraub WS, Moran AE, Shen J (2020). Estimating the optimal individualized treatment rule from a cost-effectiveness perspective. Biometrics, 78(1), 337-351.
  70. Brown SM, Peltan I, Kumar N, Leither L, Webb BJ, Starr N, Grissom CK, Buckel WR, Srivastava R, Butler AM, Groat D, Haaland B, Ying J, Harris E, Johnson S, Paine R 3rd, Greene T (2020). Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with COVID-19 (HAHPS): Results of a Randomized, Active Comparator Trial. Ann Am Thorac Soc.
  71. Akhlaghi N, Needham DM, Bose S, Banner-Goodspeed VM, Beesley SJ, Dinglas VD, Groat D, Greene T, Hopkins RO, Jackson J, Mir-Kasimov M, Sevin CM, Wilson E, Brown SM (2020). Evaluating the association between unmet healthcare needs and subsequent clinical outcomes: protocol for the Addressing Post-Intensive Care Syndrome-01 (APICS-01) multicentre cohort study. BMJ Open, 10(10), e040830.
  72. Brintz BJ, Howard JI, Haaland B, Platts-Mills JA, Greene T, Levine AC, Nelson EJ, Pavia AT, Kotloff KL, Leung DT (2020). Clinical predictors for etiology of acute diarrhea in children in resource-limited settings. PLoS Negl Trop Dis, 14(10), e0008677.
  73. Heerspink HJL, Stefnsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjstrm CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators (2020). Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 383(15), 1436-1446.
  74. Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Grriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjstrm CD, Langkilde AM, Heerspink HJL (2020). The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant, 35(10), 1700-1711.
  75. Coon ER, Destino LA, Greene TH, Vukin E, Stoddard G, Schroeder AR (2020). Comparison of As-Needed and Scheduled Posthospitalization Follow-up for Children Hospitalized for Bronchiolitis: The Bronchiolitis Follow-up Intervention Trial (BeneFIT) Randomized Clinical Trial. JAMA Pediatr, 174(9), e201937.
  76. Johnson JT, Sullivan KL, Nelson RE, Sheng X, Greene TH, Bailly DK, Eckhauser AW, Marino BS, Minich LL, Pinto NM (2020). Factors That Contribute to Cost Differences Based on ICU of Admission in Neonates Undergoing Congenital Heart Surgery: A Novel Decomposition Analysis. Pediatr Crit Care Med, 21(9), e842-e847.
  77. Ilkun OL, Greene T, Cheung AK, Whelton PK, Wei G, Boucher RE, Ambrosius W, Chertow GM, Beddhu S (2020). The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes. Diabetes Care, 43(8), 1878-1884.
  78. Brown SM, Peltan ID, Webb B, Kumar N, Starr N, Grissom C, Buckel WR, Srivastava R, Harris ES, Leither LM, Johnson SA, Paine R 3rd, Greene T (2020). Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial. Ann Am Thorac Soc, 17(8), 1008-1015.
  79. Skolasky RL, Wegener ST, Aaron RV, Ephraim P, Brennan G, Greene T, Lane E, Minick K, Hanley AW, Garland EL, Fritz JM (2020). The OPTIMIZE study: protocol of a pragmatic sequential multiple assessment randomized trial of nonpharmacologic treatment for chronic, nonspecific low back pain. BMC Musculoskelet Disord, 21(1), 293.
  80. Jardine MJ, Zhou Z, Mahaffey KW, Oshima M, Agarwal R, Bakris G, Bajaj HS, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Di Tanna GL, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Qiu R, Sun T, Wheeler DC, Zhang H, Zinman B, Rosenthal N, Perkovic V, CREDENCE Study Investigators (2019). Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol, 31(5), 1128-1139.
  81. Jones BE, Ying J, Stevens V, Haroldsen C, He T, Nevers M, Christensen MA, Nelson RE, Stoddard GJ, Sauer BC, Yarbrough PM, Jones MM, Goetz MB, Greene T, Samore MH (2020). Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia. JAMA Intern Med, 180(4), 552-560.
  82. Chang TI, Wei G, Boucher R, Kramer H, Chertow GM, Cheung AK, Greene T, Whelton PK, Beddhu S (2020). Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease. Kidney360, 1(5), 368-375.
  83. Staub J, Siddiqui A, Murphy M, Lam R, Parikh M, Pleskow D, Papachristou G, Sharaiha R, Iqbal U, Loren D, Kowalski T, Noor A, Mumtaz T, Yasuda I, Thomas S, Hsaeeb A, Herrick J, Greene T, Adler DG (2020). Unilateral versus bilateral hilar stents for the treatment of cholangiocarcinoma: a multicenter international study. Ann Gastroenterol, 33(2), 202-209.
  84. Raphael KL, Greene T, Wei G, Bullshoe T, Tuttle K, Cheung AK, Beddhu S (2020). Sodium Bicarbonate Supplementation and Urinary TGF-β1 in Nonacidotic Diabetic Kidney Disease: A Randomized, Controlled Trial. Clin J Am Soc Nephrol, 15(2), 200-208.
  85. Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC, DAPA-CKD Investigators (2019). Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant, 35(2), 274-282.
  86. Fernandez ME, Schlechter CR, Del Fiol G, Gibson B, Kawamoto K, Siaperas T, Pruhs A, Greene T, Nahum-Shani I, Schulthies S, Nelson M, Bohner C, Kramer H, Borbolla D, Austin S, Weir C, Walker TW, Lam CY, Wetter DW (2020). QuitSMART Utah: an implementation study protocol for a cluster-randomized, multi-level Sequential Multiple Assignment Randomized Trial to increase Reach and Impact of tobacco cessation treatment in Community Health Centers. Implement Sci, 15(1), 9.
  87. Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, Greene T, Tighiouart H, Matsushita K, Ballew SH, Sang Y, Vonesh E, Ying J, Manley T, de Zeeuw D, Eckardt KU, Levin A, Perkovic V, Zhang L, Willis K (2019). Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis, 75(1), 84-104.
  88. Levey AS, Coresh J, Tighiouart H, Greene T, Inker LA (2019). Measured and estimated glomerular filtration rate: current status and future directions. Nat Rev Nephrol, 16(1), 51-64.
  89. Torrecillas V, Allen CM, Greene T, Park A, Chung W, Lanzieri TM, Demmler-Harrison G (2019). Should You Follow the Better-Hearing Ear for Congenital Cytomegalovirus Infection and Isolated Sensorineural Hearing Loss? Otolaryngol Head Neck Surg, 162(1), 114-120.
  90. Nkoy FL, Wilkins VL, Fassl BA, Johnson JM, Uchida DA, Poll JB, Greene TH, Koopmeiners KJ, Reynolds CC, Valentine KJ, Savitz LA, Maloney CG, Stone BL (2019). Contextual Factors Influencing Implementation of Evidence-Based Care for Children Hospitalized With Asthma. Hosp Pediatr, 9(12), 949-957.
  91. Rathi N, Whelton PK, Chertow GM, Cushman WC, Cheung AK, Wei G, Boucher R, Kimmel PL, Bress AP, Kramer HJ, Al-Marji C, Greene T, Beddhu S (2019). Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events. Am J Hypertens, 32(12), 1170-1177.
  92. Vonesh E, Tighiouart H, Ying J, Heerspink HL, Lewis J, Staplin N, Inker L, Greene T (2019). Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. Stat Med, 38(22), 4218-4239.
  93. Inker LA, Heerspink HJL, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, Simon AL, Ying J, Beck GJ, Wanner C, Floege J, Li PK, Perkovic V, Vonesh EF, Greene T (2019). GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. J Am Soc Nephrol, 30(9), 1735-1745.
  94. Greene T, Ying J, Vonesh EF, Tighiouart H, Levey AS, Coresh J, Herrick JS, Imai E, Jafar TH, Maes BD, Perrone RD, Del Vecchio L, Wetzels JFM, Heerspink HJL, Inker LA (2019). Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation. J Am Soc Nephrol, 30(9), 1756-1769.
  95. Cho ME, Hansen JL, Peters CB, Cheung AK, Greene T, Sauer BC (2019). An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. Kidney Int, 96(3), 750-760.
  96. Lanphear BP, Hornung R, Khoury J, Yolton K, Baghurst P, Bellinger DC, Canfield RL, Dietrich KN, Bornschein R, Greene T, Rothenberg SJ, Needleman HL, Schnaas L, Wasserman G, Graziano J, Roberts R (2019). Erratum: "Low-Level Environmental Lead Exposure and Children's Intellectual Function: An International Pooled Analysis". Environ Health Perspect, 127(9), 99001.
  97. Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V (2019). Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 140(9), 739-750.
  98. Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene T (2019). Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. J Am Soc Nephrol, 30(8), 1523-1533.
  99. Derington CG, Gums TH, Bress AP, Herrick JS, Greene TH, Moran AE, Weintraub WS, Kronish IM, Morisky DE, Trinkley KE, Saseen JJ, Reynolds K, Bates JT, Berlowitz DR, Chang TI, Chonchol M, Cushman WC, Foy CG, Herring CT, Katz LA, Krousel-Wood M, Pajewski NM, Tamariz L, King JB, SPRINT Research Group (2019). Association of Total Medication Burden With Intensive and Standard Blood Pressure Control and Clinical Outcomes: A Secondary Analysis of SPRINT. Hypertension, HYPERTENSIONAHA11912907.
  100. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med, 380(24), 2295-2306.
  101. Nkoy FL, Fassl BA, Wilkins VL, Johnson J, Unsicker EH, Koopmeiners KJ, Jensen A, Frazier M, Gaddis J, Malmgren L, Williams S, Oldroyd H, Greene T, Sheng X, Uchida DA, Maloney CG, Stone BL (2019). Ambulatory Management of Childhood Asthma Using a Novel Self-management Application. Pediatrics, 143(6).
  102. Inker LAGrams MELevey ASCoresh JCirillo MCollins JFGansevoort RTGutierrez OMHamano THeine GHIshikawa SJee SHKronenberg FLandray MJMiura KNadkarni GNPeralta CARothenbacher DSchaeffner ESedaghat SShlipak MGZhang Lvan Zuilen ADHallan SIKovesdy CPWoodward MLevin AAstor BAppel LGreene TChen TChalmers JArima HPerkovic VYatsuya HTamakoshi KLi YHirakawa YMatsushita KSang YPolkinghorne KChadban SAtkins RDjurdjev OLiu LZhao MWang FWang JEbert NMartus PTang MEmrich ISeiler SZawada ANally JNavaneethan SSchold JSarnak MKatz RHiramoto JIso HYamagishi KUmesawa MMuraki IFukagawa MMaruyama SHasegawa TFujii NWheeler DEmberson JTownend JBrenner HSchttker BSaum KUFox CHwang SJKttgen ASchneider MPEckardt KUGreen JKirchner HLChang ARHo KIto SMiyazaki MNakayama MYamada GIrie FSairenchi TYano YKotani KNakamura TKimm HMok YChodick GShalev VWetzels JFMBlankestijn PJvan den Brand JKollerits B (2019). Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium. Am J Kidney Dis, 73(2), 206-217.
  103. Hammers DB, Foster NL, Hoffman JM, Greene TH, Duff K (2019). Neuropsychological, Psychiatric, and Functional Correlates of Clinical Trial Enrollment. J Prev Alzheimers Dis, 6(4), 242-247.
  104. Gou EWeng CGreene TAnderson KEPhillips JD (2018). Longitudinal Analysis of Erythrocyte and Plasma Protoporphyrin Levels in Patients with Protoporphyria. J Appl Lab Med, 3(2), 213-221.
  105. Zuk A, Palevsky PM, Fried L, Harrell FE Jr, Khan S, McKay DB, Devey L, Chawla L, de Caestecker M, Kaufman JS, Thompson BT, Agarwal A, Greene T, Okusa MD, Bonventre JV, Dember LM, Liu KD, Humphreys BD, Gossett D, Xie Y, Norton JM, Kimmel PL, Star RA (2018). Overcoming Translational Barriers in Acute Kidney Injury: A Report from an NIDDK Workshop. Clin J Am Soc Nephrol, 13(7), 1113-1123.
  106. Li L, Luo S, Hu B, Greene T (2017). Dynamic Prediction of Renal Failure Using Longitudinal Biomarkers in a Cohort Study of Chronic Kidney Disease. Stat Biosci, 9(2), 357-378.
  107. Baigent CHerrington WGCoresh JLandray MJLevin APerkovic VPfeffer MARossing PWalsh MWanner CWheeler DCWinkelmayer WCMcMurray JJVAbu-Alfa AArchdeacon PBlock GACaskey FJCheung AKCooper BCraig JCDember LMEknoyan GGansevoort RTGill JSGillespie BGreene THarris DCHaynes RHemmelgarn BRHerzog CAHiemstra TFInker LAJardine MJJha VJiang LJohansen KLKewalramani RLambers Heerspink HJLefkowitz MLok CELoud FMaiulaitis RMaddux DWMaddux FWMadero MMariz SMauer MNally JVNangaku MOkpechi IGParfrey PSPecoits-Filho RPereira BJGRocco MVRossignol PSchaefer FTentori FThompson ATonelli MTong AToto RDTuttle KRVetter TMoon Wang AYZannad F (2017). Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int, 92(2), 297-305.
  108. Unruh MLLarive BEggers PWGarg AXGassman JJFinkelstein FOKimmel PLChertow GMAchinger SAnderson SAppel LApruzzes RAtwal JAugustine BAyus JBardsley JBay WBeach SBeck GBharti BBriggs JBullas RBurkart JBurrowes JCabezon ECallegari JCarter MChampagne JChan CChan WChang JCheung ACopland MCoplon NCoppley ADaugirdas JDellagrottaglie SDepner TDerse ADominguez ADoss SEknoyan GEscalada RFensterer AFofie YFranzwa BFrome RFu ZGayda PGeller NGeronemus RGoodman WGorodetskaya IGotch FGreene TGreenwood RGrimm RGutierrez MHall YHandelman GHenderson LHernandez AHiggins HHilkin AHostetter THoy CHumphreys MHunsicker LJames SKariisa MKaufman AKaufman TKaysen GKe SKeene RKliger AKotanko PKramer CKuhlmann MKwan SKwok SLacson ELeavell ELemus DLevin ALevin NLi MLilli KLindsay RLockridge RLuan JMackrell JManaster RMandaci OMathew RMauck VMazzorato AMcCulloch CMcGrath-Chong MMcLeroy S (2016). The effect of frequent hemodialysis on self-reported sleep quality: Frequent Hemodialysis Network Trials. Nephrol Dial Transplant, 31(6), 984-991.
  109. Gallicchio L, Miller SR, Kiefer J, Greene T, Zacur HA, Flaws JA (2015). The Associations Between Body Mass Index, Smoking, and Alcohol Intake with Ovarian Volume in Midlife Women. J Womens Health (Larchmt), 25(4), 409-15.
  110. Farber AImrey PBHuber TSKaufman JMKraiss LWLarive BLi LFeldman HIDember LStern LLesage PKivork CSoares DMalikova MAllon MYoung CTaylor MWoodard LMangadi KRoy-Chaudhury PMunda RLee TAlloway REl-Khatib MCanaan TPflum AThieken LCampos-Naciff BBerceli SJansen MMcCaslin GTrahan YVazquez MVongpatanasin WDavidson IHwang CLightfoot TLivingston CValencia ADolmatch BFenves AHawkins NCheung AKinikini DTreiman GIhnat DSarfati MLavasani IMaloney MSchlotfeldt LHimmelfarb JBuchanan CClark CCrawford CHamlett JKundzins JManahan LWise JBeck GGassman JGreene TAlster JLi MMackrell JRadeva MWeiss BWiggins KAlpers CHudkins KWietecha TRobbin MUmphrey HAlexander LAbts CBelt LVita JHamburg NDuess MLevit AHiggins HKe SMandaci OSnell CGravley JBehnken SMortensen RChertow GBesarab ABrayman KDiener-West MHarrison DInker LLouis TMcClellan WRubin JKusek JStar R (2016). Multiple preoperative and intraoperative factors predict early fistula thrombosis in the Hemodialysis Fistula Maturation Study. J Vasc Surg, 63(1), 163-170.e6.
  111. Beckmann JT, Wylie JD, Potter MQ, Maak TG, Greene TH, Aoki SK (2015). Effect of Naproxen Prophylaxis on Heterotopic Ossification Following Hip Arthroscopy: A Double-Blind Randomized Placebo-Controlled Trial. J Bone Joint Surg Am, 97(24), 2032-7.
  112. Thomas A, Redd A, Khader K, Leecaster M, Greene T, Samore M (2015). Efficient parameter estimation for models of healthcare-associated pathogen transmission in discrete and continuous time. Math Med Biol, 32(1), 79-98.
  113. Khader K, Leecaster M, Greene T, Samore M, Thomas A (2014). Improved hidden Markov model for nosocomial infections. Math Med Biol, 31(4), 338-52.
  114. Suri RSLarive BHall YKimmel PLKliger ASLevin NTamura MKChertow GMLevin NWBeck GJDepner TAEggers PGassman JJGorodetskaya IGreene TJames SLindsay RMMehta RLMiller BOrnt DBRajagopalan SRastogi ARocco MVSchiller BSergeyeva OSchulman GTing GOUnruh MLStar RALockridge RSChan CTCopland MHoy CDPierratos APipkin MFStokes JBBriggs JHostetter TNarva AStar RAAugustine BMohr PFu ZDaugirdas JHunsicker LLi MMackrell JWiggins KSherer SWeiss BSanz JDellagrottaglie SKariisa MTran TWest JKeene RSchlarb JMcGrath-Chong MFrome RHiggins HKe SMandaci OOwens CSnell CEknoyan GAppel LCheung ADerse AKramer CGeller NGrimm RHenderson LPrichard SRoecker ERiley JSchuessler RPeterson CFensterer ASteigerwald DSomers DHilkin ALilli KWallace WFranzwa BWaterman ELevin ASioson LCabezon EKwan SRoger DChampagne JBullas RGarg AMazzorato ASpanner EBurkart JMoossavi SMauck VKaufman TChan W (2014). Effects of frequent hemodialysis on perceived caregiver burden in the frequent hemodialysis network trials. Clin J Am Soc Nephrol, 9(5), 936-942.
  115. Wen CPMatsushita KCoresh JIseki KIslam MKatz RMcClellan WPeralta CAWang HYDe Zeeuw DAstor BCGansevoort RTLevey ASLevin AWright JTAppel LGreene TChalmers JMacMahon SWoodward MArima HYatsuya HYamashita KToyoshima HTamakoshi KSang YAtkins RCPolkinghorne KRChadban SShankar AKlein RKlein BEKLee KEWang FZhang LZuo LLiu LDjurdjev OTonelli MSacks FCurhan GShlipak MFried LIso HKitamura AOhira TYamagishi KJafar THHatcher JPoulter NChaturvedi NLandray MJEmberson JTownend JWheeler DCRothenbacher DBrenner HMller HSchttker BFox CSHwang SJMeigs JBPerkins RMFluck NClark LPrescott GJMarks ABlack CCirillo MHallan SAasard Kien CMRadtke MIrie FSairenchi TSmith DHWeiss JJohnson ESThorp MLCollins AJVassalotti JALi SChen SCLee BJWetzels JFBlankestijn PJVan Zuilen ADSarnak MInker LMenon VFried LFKramer HDe Boer IKronenberg FKollerits BRitz ERoderick PNitsch DFletcher ABulpitt C (2014). Relative risks of chronic kidney disease for mortality and end-stage renal disease across races are similar. Kidney Int, 86(4), 819-827.
  116. Jones M, Ying J, Huttner B, Evans M, Maw M, Nielson C, Rubin MA, Greene T, Samore MH (2014). Relationships between the importation, transmission, and nosocomial infections of methicillin-resistant Staphylococcus aureus: an observational study of 112 Veterans Affairs Medical Centers. Clin Infect Dis, 58(1), 32-9.
  117. Greene T, Joffe M, Hu B, Li L, Boucher K (2013). The balanced survivor average causal effect. Int J Biostat, 9(2), 291-306.
  118. Budtz-Jrgensen EBellinger DLanphear BGrandjean PHornung RKhoury JYolton KBaghurst PCanfield RLDietrich KNBornschein RGreene TRothenberg SJNeedleman HLSchnaas LWasserman GGraziano JRoberts R (2013). An international pooled analysis for obtaining a benchmark dose for environmental lead exposure in children. Risk Anal, 33(3), 450-461.
  119. Hu B, Li L, Wang X, Greene T (2012). Nonparametric multistate representations of survival and longitudinal data with measurement error. Stat Med, 31(21), 2303-17.
  120. Mayer J, Greene T, Howell J, Ying J, Rubin MA, Trick WE, Samore MH, CDC Prevention Epicenters Program (2012). Agreement in classifying bloodstream infections among multiple reviewers conducting surveillance. Clin Infect Dis, 55(3), 364-70.
  121. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I, Collaborative Study Group (2011). Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis, 58(5), 729-36.
  122. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, HOST Investigators (2011). FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol, 22(10), 1913-22.
  123. Yan G, Greene T (2011). Statistical analysis and design for estimating accuracy in clinical-center classification of cause-specific clinical events in clinical trials. Clin Trials, 8(5), 571-80.
  124. Leecaster M, Gesteland P, Greene T, Walton N, Gundlapalli A, Rolfs R, Byington C, Samore M (2011). Modeling the variations in pediatric respiratory syncytial virus seasonal epidemics. BMC Infect Dis, 11, 105.
  125. Chertow GLevin NBeck GDepner TEggers PGassman JGorodetskaya IGreene TJames SLarive BLindsay RMehta RMiller BOrnt DRajagopalan SRastogi ARocco MSchiller BSergeyeva OSchulman GTing GUnruh MStar RKliger A (2010). In-center hemodialysis six times per week versus three times per week. N Engl J Med, 363(24), 2287-2300.
  126. Rogers RKStehlik JStoddard GJGreene TCollins SPPeacock WFMaisel ADClopton PMichaels AD (2010). Erratum: Corrigendum to 'Adjusting for clinical covariates improves the ability of b-type natriuretic peptide to distinguish cardiac from non-cardiac dyspnoea: A sub-study of HEARD-IT' (Eur J Heart Fail (2009) 11 (1043-1049)). Eur J Heart Fail, 12(5), 524-525.
  127. Kevin Rogers R, Stehlik J, Stoddard GJ, Greene T, Collins SP, Peacock WF, Maisel AD, Clopton P, Michaels AD (2009). Adjusting for clinical covariates improves the ability of B-type natriuretic peptide to distinguish cardiac from non-cardiac dyspnoea: a sub-study of HEARD-IT. Eur J Heart Fail, 11(11), 1043-9.
  128. Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley-Brown D, Phillips RA, African American Study of Hypertension and Kidney Disease Collaborative Research Group (2009). Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med, 169(17), 1587-94.
  129. Joffe MM, Greene T (2008). Related causal frameworks for surrogate outcomes. Biometrics, 65(2), 530-8.
  130. Greene T, Daugirdas JT, Depner TA, Gotch F, Kuhlman M, Frequent Hemodialysis Network Study Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (2009). Solute clearances and fluid removal in the frequent hemodialysis network trials. Am J Kidney Dis, 53(5), 835-44.
  131. Rubin MA, Mayer J, Greene T, Sauer BC, Hota B, Trick W, Jernigan JA, Samore MH (2008). An agent-based model for evaluating surveillance methods for catheter-related bloodstream infection. AMIA Annu Symp Proc, 631-5.
  132. Levey ASCoresh JGreene TStevens LAZhang YHendriksen S (2008). Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate (Annals of Internal Medicine (2006) 145, (247-254)). Ann Intern Med, 149(7), 519.
  133. Appel LJ, Wright JT Jr, Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY, African American Study of Kidney Disease and Hypertension Collaborative Research Group (2008). Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med, 168(8), 832-9.
  134. Garg AX, Greene T, Levin NW (2007). A well-conducted randomized trial that establishes no benefit of therapy is an important medical advance. Nephrol Dial Transplant, 23(1), 52-5.
  135. Samore MH, Shen S, Greene T, Stoddard G, Sauer B, Shinogle J, Nebeker J, Harbarth S (2007). A simulation-based evaluation of methods to estimate the impact of an adverse event on hospital length of stay. Med Care, 45(10 Supl 2), S108-15.
  136. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration (2007). Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem, 53(4), 766-72.
  137. Suri RS, Garg AX, Chertow GM, Levin NW, Rocco MV, Greene T, Beck GJ, Gassman JJ, Eggers PW, Star RA, Ornt DB, Kliger AS, Frequent Hemodialysis Network Trial Group (2006). Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int, 71(4), 349-59.
  138. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J, AASK Study Group (2006). Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis, 48(5), 739-51.
  139. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration (2006). Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med, 145(4), 247-54.
  140. Stevens LA, Greene T, Levey AS (2006). Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol, 1(4), 874-84.
  141. Dixon BSBeck GJDember LMDepner TAGassman JJGreene THimmelfarb JHunsicker LGKaufman JSLawson JHMeyers CMMiddleton JPRadeva MSchwab SJWhiting JFFeldman HI (2006). Erratum: Design of the Dialysis Access Consortium (DAC) aggrenox prevention of access stenosis trial (Clinical Trials 2 (400-412)). Clin Trials, 3(2), 160.
  142. Stevens LA, Coresh J, Greene T, Levey AS (2006). Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med, 354(23), 2473-83.
  143. Lash JP, Wang X, Greene T, Gadegbeku CA, Hall Y, Jones K, Kusek JW, Sika M, Unruh M, African American Study of Kidney Disease and Hypertension Trial Study Group (2006). Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management. Am J Kidney Dis, 47(6), 956-64.
  144. Menon V, Sarnak MJ, Greene T, Wang X, Pereira AA, Beck GJ, Kusek JW, Selhub J, Collins AJ, Levey AS, Shlipak MG (2006). Relationship between homocysteine and mortality in chronic kidney disease. Circulation, 113(12), 1572-7.
  145. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL (2005). The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med, 165(8), 947-53.
  146. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM (2004). Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol, 16(2), 459-66.
  147. Ogiste JS, Nejat RJ, Rashid HH, Greene T, Gupta M (2003). The role of mannitol in alleviating renal injury during extracorporeal shock wave lithotripsy. J Urol, 169(3), 875-7.
  148. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R, Hemodialysis HEMO Study Group (2002). Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med, 347(25), 2010-9.
  149. Sarnak MWang SBeck GKusek JSelhub JGreene TLevey A (2002). Homocysteine, cysteine, and B vitamins as predictors of kidney disease progression. Am J Kidney Dis, 40(5), 932-939.
  150. Ray PAcheson DChitrakar RCnaan AGibbs KHirschman GHChristen ETrachtman HIngelfinger JBriggs JKusek JCattran DCohen MBFreeman KGreene TMoshe SSchulman SSpringate JKaskel FWhyte DWeiss RMcKay CReisman LPerelstein EChandra MSalcedo JWeiss LVarade WFord DChan JRestaino INagaraj SNorwood VForeman JMoritz MMahan JMoxey-Mims MWarshaw BYiu VBrem ABartosh SAndreoli SMilner LGoebel JMuchant DHanevold C (2002). Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome. J Am Soc Nephrol, 13(3), 699-707.
  151. Beddhu SKaysen GYan GSarnak MAgodoa LOrnt DCheung AGreene TBeck GGassman J (2002). Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis, 40(4), 721-727.
  152. Greene T (2001). A model for a proportional treatment effect on disease progression. Biometrics, 57(2), 354-60.
  153. Hebert LA, Kusek JW, Greene T, Agodoa LY, Jones CA, Levey AS, Breyer JA, Faubert P, Rolin HA, Wang SR (1997). Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension, 30(3 Pt 1), 428-35.
  154. Levey ASAdler SCaggiula AWEngland BKGreene THunsicker LGKusek JWRogers NLTeschan PE (1996). Effects of dietary protein restriction on the progression of moderate renal disease in the modification of diet in renal disease study: Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol, 7(12), 2616-2626.
  155. Levey ASBeck GJBosch JPCaggiula AWGreene THunsicker LGKlahr S (1996). Short-Term Effects of Protein Intake, Blood Pressure, and Antihypertensive Therapy on Glomerular Filtration Rate in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol, 7(10), 2097-2109.
  156. Nelson SGreene TErnhart C (1996). Toxocara canis infection in preschool age children: Risk factors and the cognitive development of preschool children. Neurotoxicol Teratol, 18(2), 167-174.
  157. Coggins CHDwyer JTGreene TPetot GSnetselaar LGLente FV (1994). Serum Lipid Changes Associated With Modified Protein Diets: Results From the Feasibility Phase of the Modification of Diet in Renal Disease Study. Am J Kidney Dis, 23(4), 514-523.
  158. Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, Molitch ME, Mitch WE, Siebert C, Hall PM (1993). Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol, 4(5), 1159-71.
  159. Iglesias AA, Barry GF, Meyer C, Bloksberg L, Nakata PA, Greene T, Laughlin MJ, Okita TW, Kishore GM, Preiss J (1993). Expression of the potato tuber ADP-glucose pyrophosphorylase in Escherichia coli. J Biol Chem, 268(2), 1081-6.
  160. Greene T, Ernhart CB (1991). Adjustment for cofactors in pediatric research. J Dev Behav Pediatr, 12(6), 378-85.
  161. Ernhart CB, Greene T (1990). Low-level lead exposure in the prenatal and early preschool periods: language development. Arch Environ Health, 45(6), 342-54.


  1. Siew EDLiu KDBonn JChinchilli VDember LMGirard TDGreene THernandez AFAlp Ikizler TJames MTKampschroer KKopp JBLevy MPalevsky PMPannu NParikh CRRocco MVSilver SAThiessen-Philbrook HWald RXie YKimmel PLStar RA (2020). Improving care for patients after hospitalization with AKI. [Review]. J Am Soc Nephrol, 31(10), 2237-2241.


  1. Li L, Yang W, Astor BC, Greene T (2019). Competing Risk Modeling: Time to Put it in Our Standard Analytical Toolbox. J Am Soc Nephrol, 30(12), 2284-2286.
  2. Greene T, Li L (2017). From Static to Dynamic Risk Prediction: Time Is Everything. Am J Kidney Dis, 69(4), 492-494.
  3. Cheung AK, Greene T (2009). Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol, 20(3), 462-4.


  1. Yan G, Nee R, Scialla JJ, Greene T, Yu W, Cheung AK, Norris KC (2022). Estimation of Black-White Disparities in CKD Outcomes: Comparison Using the 2021 Versus the 2009 CKD-EPI Creatinine Equations [Letter to the editor]. Am J Kidney Dis, 80(3), 423-426.
  2. Inker LAHeerspink HJLVonesh EFGreene T (2022). Letter by Inker et al Regarding Article, "Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failure" [Letter to the editor]. Circ Heart Fail, 15(3), E008983.
  3. Sarraju A, Li JW, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KW (2021). Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial [Letter to the editor]. Am Heart J, 233, 141-148.
  4. Presson AP, Greene TH, Ou Z, Zhang C, Tyser AR, Kazmers NH (2021). Reply to "The Problem of Collinearity in Mental Health and Patient Reported Outcome Research". [Letter to the editor]. J Hand Surg Am, 46(2), e3-e6.
  5. Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW (2019). Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. [Letter to the editor]. Circulation, 141(5), 407-410.
  6. Levey AS, Coresh J, Tighiouart H, Greene T, Inker LA (2019). Strengths and limitations of estimated and measured GFR. [Letter to the editor]. Nat Rev Nephrol, 15(12), 784.
  7. Beddhu S, Chertow GM, Cheung AK, Cushman WC, Greene T, Wei G, Boucher R, Whelton PK, SPRINT Research Group (2018). Response by Beddhu et al to Letters Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control". [Letter to the editor]. Circulation, 137(24), 2668-2669.
  8. Brown KA, Daneman N, Stevens V, Greene TH, Arora P (2016). Reply to Wolkewitz: When to Use Cumulative Risk-Based Versus Rate-Based Approaches in the Analysis of Hospital-Acquired Infection Risk Factors? That Depends on the Question. [Letter to the editor]. Infect Control Hosp Epidemiol, 37(9), 1124-5.
  9. Joseph JV, Greene T (2007). Re: Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1% K. Touijer, F. Rabbani, J. R. Otero, F. P. Secin, J. A. Eastham, P. T. Scardino And B. Guillonneau J Urol 2007; 178: 120-124. [Letter to the editor]. J Urol, 179(2), 789-90.


  1. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddhu S, Cheung AK, Xian W, Weintraub WS, Bress AP (2021). Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS One (16(4), pp. e0248080). United States.